glucosylceramide


Also found in: Encyclopedia, Wikipedia.

glu·co·syl·cer·a·mide

(glū'kō-sil-ser'ă-mīd),
A neutral glycolipid containing equimolar amounts of fatty acid, glucose, and sphingosine (or a derivative thereof); accumulates in people with Gaucher disease.
Synonym(s): glucocerebroside

glu·co·syl·cer·a·mide

(glū'kō-sil-ser'ă-mīd)
A neutral glycolipid containing equimolar amounts of fatty acid, glucose, and sphingosine (or a derivative thereof); accumulates in people with Gaucher disease.
Synonym(s): glucocerebroside.
References in periodicals archive ?
When these animals were treated with glucosylceramide before induction, liver failure was prevented.
EGS21 is a proprietary formulation of beta glucosylceramide, a naturally occurring gylcosphingolipid that was shown to improve hepatic steatosis, steatohepatitis and insulin resistance in animal models of non-alcoholic fatty liver disease (NAFLD) by exerting an NKT regulatory lymphocyte dependent immune modulatory effect.
EGS21, Enzo's Orally Administered Glucosylceramide Formulation, Named Among Top 10 Inflammatory/Autoimmune Projects to Watch at Meeting
Furthermore, the patients' glucosylceramide plasma levels normalized.
Binding of influenza A virus to monosialoganglioside (GM3) reconstituted in glucosylceramide and sphingomyelin membranes.
Acid [beta]-glucosidase is responsible for the cleavage of the [beta]-glucosidic bond of its primary substrate glucosylceramide, an intermediate in the catabolism of globoside and gangliosides.
Eliglustat tartrate, a novel glucosylceramide analog given orally, is designed to partially inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucosylceramide.
Silencing of either VDR, SRC2, or SRC3 resulted in decreases in specific glucosylceramide (GlcCer) species but not other lipids such as cholesterol and free fatty acids.
Gaucher's disease is an autosomal recessive lysosomal storage disorder, characterized by an accumulation of the lipid glucosylceramide in various tissues, including the bone marrow.
In substrate reduction therapy (SRT), the synthesis of glycosphingolipids is reduced by partial inhibition of glucosylceramide (G1cCer) synthase by deoxynojirimycin analogs (5), leading to reduction of the glycosphingolipid pool and eventually to reduction of the substrate load for lysosomal degradation by sphingolipid hydrolases.
Eliglustat tartrate, a novel glucosylceramide analog given orally, was designed to partially inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucosylceramide.